AMN Healthcare Shares Surge 19% on 2026 EBITDA Margin Expansion Plans Revealed
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 14 2026
0mins
Source: seekingalpha
- Stock Surge: AMN Healthcare's shares rose approximately 19% following the release of an investor slide deck at the J.P. Morgan Healthcare Conference, reflecting strong market confidence in its growth potential.
- Margin Expansion Plans: The company aims for a 50-100 basis point increase in adjusted EBITDA and gross margins by 2026, based on a normalized Q4 revenue run rate, indicating a positive outlook for future profitability.
- Sustained Growth Expectations: AMN projects a 10%-15% CAGR in adjusted EBITDA post-2026, alongside 4%-6% annual organic revenue growth, which will provide stable cash flow and investment returns for the company.
- Capex Forecast: Management has set a capital expenditure projection of $40M-$45M for 2025, which will support the company's long-term growth strategy and enhance its competitive position in the market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy AMN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on AMN
Wall Street analysts forecast AMN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AMN is 21.50 USD with a low forecast of 20.50 USD and a high forecast of 22.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Analyst Rating
3 Buy
3 Hold
1 Sell
Moderate Buy
Current: 20.490
Low
20.50
Averages
21.50
High
22.00
Current: 20.490
Low
20.50
Averages
21.50
High
22.00
About AMN
AMN Healthcare Services, Inc. is a provider of total talent solutions for healthcare organizations across the United States. The Company provides access to a comprehensive network of quality healthcare professionals through its recruitment strategies and breadth of career opportunities. Its segments include nurse and allied solutions, physician and leadership solutions, and technology and workforce solutions. The nurse and allied solutions segment includes its travel nurse staffing, labor disruption staffing, local staffing, international nurse permanent placement, and allied staffing businesses. The physician and leadership solutions segment includes its locum tenens staffing, healthcare interim leadership staffing, executive search, and physician permanent placement businesses. The technology and workforce solutions segment includes the Company’s language services, vendor management systems (VMS), workforce optimization, and outsourced solutions businesses.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
AMN Healthcare Shares Surge 19% on 2026 EBITDA Margin Expansion Plans Revealed
- Stock Surge: AMN Healthcare's shares rose approximately 19% following the release of an investor slide deck at the J.P. Morgan Healthcare Conference, reflecting strong market confidence in its growth potential.
- Margin Expansion Plans: The company aims for a 50-100 basis point increase in adjusted EBITDA and gross margins by 2026, based on a normalized Q4 revenue run rate, indicating a positive outlook for future profitability.
- Sustained Growth Expectations: AMN projects a 10%-15% CAGR in adjusted EBITDA post-2026, alongside 4%-6% annual organic revenue growth, which will provide stable cash flow and investment returns for the company.
- Capex Forecast: Management has set a capital expenditure projection of $40M-$45M for 2025, which will support the company's long-term growth strategy and enhance its competitive position in the market.
Continue Reading
Dassault Aviation Leads Harmattan AI's $200 Million Series B Funding Round
- Strategic Partnership: Dassault Aviation has formed a strategic partnership with Harmattan AI, leading its $200 million Series B funding round to accelerate the integration of controlled autonomy and AI technologies into combat aviation systems, thereby enhancing the operational capabilities of future fighter jets.
- Global Expansion: Harmattan AI has secured multiple Programs of Record from the French and UK Ministries of Defence for its autonomous systems portfolio, and the funding will be used to expand the deployment of AI-enabled missions across new operational theaters, addressing the growing global demand and enhancing its market competitiveness.
- Technology Integration: This collaboration will support Harmattan AI in developing embedded AI capabilities within Dassault Aviation's future air combat systems, such as the Rafale F5 and UCAS, particularly for unmanned aerial system control, which will improve operational efficiency and responsiveness.
- Industry Leadership: Dassault Aviation will leverage its expertise in complex military platform system architecture to support Harmattan AI, further solidifying its leadership position in the global defense market and driving innovation in autonomous defense systems.
Continue Reading